Jose J Fuster
Overview
Explore the profile of Jose J Fuster including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
2754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zuriaga M, Fuster J
Diabetologia
. 2025 Mar;
PMID: 40064675
The accumulation of acquired somatic mutations is a natural consequence of ageing, but the pathophysiological implications of these mutations beyond cancer are only beginning to be understood. Most somatic mutations...
2.
Wang Y, Sano S, Yura Y, Ke Z, Sano M, Oshima K, et al.
JCI Insight
. 2024 Nov;
9(21).
PMID: 39513360
No abstract available.
3.
Verdonschot J, Fuster J, Walsh K, Heymans S
Eur Heart J
. 2024 Oct;
PMID: 39417710
The increased sensitivity of novel DNA sequencing techniques has made it possible to identify somatic mutations in small circulating clones of haematopoietic stem cells. When the mutation affects a 'driver'...
4.
Fuster V, Garcia-Alvarez A, Devesa A, Mass V, Owen R, Quesada A, et al.
J Am Coll Cardiol
. 2024 Oct;
84(15):1391-1403.
PMID: 39357937
Background: Atherosclerosis is a dynamic process. There is little evidence regarding whether quantification of atherosclerosis extent and progression, particularly in the carotid artery, in asymptomatic individuals predicts all-cause mortality. Objectives:...
5.
Diez-Diez M, Ramos-Neble B, de la Barrera J, Silla-Castro J, Quintas A, Vazquez E, et al.
Nat Med
. 2024 Aug;
30(10):2857-2866.
PMID: 39215150
Clonal hematopoiesis, a condition in which acquired somatic mutations in hematopoietic stem cells lead to the outgrowth of a mutant hematopoietic clone, is associated with a higher risk of hematological...
6.
Zuriaga M, Yu Z, Matesanz N, Truong B, Ramos-Neble B, Asensio-Lopez M, et al.
Eur Heart J
. 2024 Aug;
45(43):4601-4615.
PMID: 39212933
Background And Aims: Somatic mutations in the TET2 gene that lead to clonal haematopoiesis (CH) are associated with accelerated atherosclerosis development in mice and a higher risk of atherosclerotic disease...
7.
Nielsen R, Fuster V, Bundgaard H, Fuster J, Johri A, Kofoed K, et al.
J Am Coll Cardiol
. 2024 May;
83(21):2112-2127.
PMID: 38777513
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide and challenges the capacity of health care systems globally. Atherosclerosis is the underlying pathophysiological entity in two-thirds of...
8.
Izzi B, Fuster J
Hamostaseologie
. 2024 Feb;
44(1):13-20.
PMID: 38417801
Acquired mutations that lead to clonal hematopoiesis have emerged as a new and potent risk factor for atherosclerotic cardiovascular disease and other cardiovascular conditions. Human sequencing studies and experiments in...
9.
Zuriaga M, Pascual-Figal D, Fuster J
Eur Heart J
. 2024 Feb;
45(10):806-808.
PMID: 38320247
No abstract available.
10.
Salloum F, Tocchetti C, Ameri P, Ardehali H, Asnani A, de Boer R, et al.
JACC CardioOncol
. 2024 Jan;
5(6):715-731.
PMID: 38205010
Despite improvements in cancer survival, cancer therapy-related cardiovascular toxicity has risen to become a prominent clinical challenge. This has led to the growth of the burgeoning field of cardio-oncology, which...